SlideShare uma empresa Scribd logo
1 de 100
Surviving Sepsis Campaign Guidelines for Management of Severe Sepsis/Septic Shock An Overview
Surviving Sepsis A global program to: Reduce mortality rates in severe sepsis
Phase 1  Barcelona declaration Phase 2  Evidence based guidelines Phase 3  Implementation and education Surviving Sepsis
Phase 1  Barcelona declaration Phase 2  Evidence based guidelines Phase 3  Implementation and education Surviving Sepsis
Sponsoring Organizations ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Guidelines Committee* ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Ramsay Zimmerman  Beale Bonten Brun-Buisson Carcillo Cordonnier Dellinger (EP) Dhainaut Finch Finfer Fourrier Sprung Torres Vendor Bennet Bochud Cariou Murphy Nitsun Szokol Trzeciak Visonneau *Primary investigators from recently performed positive trials with implications for septic patients excluded from committee selection.
Surviving Sepsis Campaign (SSC) Guidelines for Management of Severe Sepsis and Septic Shock Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, Gea-Banacloche J, Keh D, Marshall JC, Parker MM, Ramsay G, Zimmerman JL, Vincent JL, Levy MM and the SSC Management Guidelines Committee Crit Care Med  2004;32:858-873 Intensive Care Med  2004;30:536-555 available online at  www.springerlink.com www.sccm.org www.sepsisforum.com
Sackett DL.  Chest  1989; 95:2S–4S Sprung CL, Bernard GR, Dellinger RP.  Intensive Care Medicine  2001; 27(Suppl):S1-S2
Clarifications  ,[object Object],[object Object]
Initial Resuscitation
Figure B, page 948, reproduced with permission from Dellinger RP. Cardiovascular management of septic shock.  Crit Care Med  2003;31:946-955.
The Importance of Early Goal-Directed Therapy for Sepsis Induced Hypoperfusion  Adapted from Table 3, page 1374, with permission from Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock.  N Engl J Med  2001; 345:1368-1377 In-hospital mortality  (all patients) 0 10 20 30 40 50 60 Standard therapy EGDT 28-day  mortality   60-day  mortality  NNT to prevent 1 event (death) = 6-8 Mortality (%)
Initial Resuscitation ,[object Object],[object Object],[object Object]
Adapted  from Table 4, page 2731, with permission from LeDoux, Astiz ME, Carpati CM, Rackow ED. Effects of perfusion pressure on tissue perfusion in septic shock.  Crit Care Med  2000; 28:2729-2732 MAP Urinary  output (mL) 49  + 18 56  +  21 43  + 13 .60/.71 Capillary blood flow (mL/min/100 g) 6.0  +  1.6 5.8  +  11 5.3  +  0.9 .59/.55 Red Cell  Velocity (au) 0.42  +  0.06 0.44  + 016 0.42  +  0.06 .74/.97 Pico 2  (mm Hg) 41  +  2 47  +  2 46  +  2 .11/.12 Pa-Pico 2  (mm Hg) 13  +  3 17  +  3 16  +  3 .27/.40 75 mm Hg 65 mm Hg 85 mm Hg F/LT
Initial Resuscitation ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Initial Resuscitation ,[object Object],[object Object],[object Object],[object Object],[object Object]
Diagnosis ,[object Object],[object Object],[object Object],[object Object],[object Object]
Antibiotic Therapy ,[object Object],[object Object]
Antibiotic Therapy ,[object Object],[object Object],[object Object]
Antibiotic Therapy ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Source Control ,[object Object],[object Object],[object Object],[object Object],[object Object]
Photograph used with permission from Janice L. Zimmerman, MD
EKG tracing reproduced with permission from Janice L. Zimmerman, MD
Fluid Therapy ,[object Object],[object Object]
Figure 2, page 206, reproduced with permission from Choi PT, Yip G, Quinonez L, Cook DJ. Crystalloids vs. colloids in fluid resuscitation: A systematic review.  Crit Care Med  1999; 27:200–210
Fluid Therapy ,[object Object],[object Object],[object Object],[object Object],[object Object]
Vasopressors ,[object Object],[object Object],[object Object],[object Object]
Effects of Dopamine, Norepinephrine, and Epinephrine on the Splanchnic Circulation in Septic Shock Figure 2, page 1665, reproduced with permission from De Backer D, Creteur J, Silva E, Vincent JL. Effects of dopamine, norepinephrine, and epinephrine on the splanchnic circulation in septic shock: Which is best?  Crit Care Med  2003; 31:1659-1667
Vasopressors ,[object Object],[object Object],Bellomo R, et al.  Lancet  2000; 356:2139-2143
Vasopressors ,[object Object],[object Object]
Circulating Vasopressin Levels in Septic Shock Figure 2, page 1755 reproduced with permission from Sharshar T, Blanchard A, Paillard M, et al. Circulating vasopressin levels in septic shock.  Crit Care Med  2003; 31:1752-1758
Vasopressin and Septic Shock ,[object Object],[object Object],[object Object]
Vasopressors Vasopressin ,[object Object],[object Object],[object Object],[object Object]
During Septic Shock Images used with permission from Joseph E. Parrillo, MD 10 Days Post Shock Diastole Systole Diastole Systole
Inotropic Therapy ,[object Object],[object Object],[object Object]
Inotropic Therapy ,[object Object],[object Object],[object Object],[object Object],[object Object]
Figure 2A, page 867, reproduced with permission from Annane D, S ébille V, Charpentier C,  et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock.  JAMA  2002; 288:862-871 Steroid Therapy
Figure 2 and Figure 3, page 648, reproduced with permission from Bollaert PE, Charpentier C, Levy B, et al. Reversal of late septic shock with supraphysiologic doses of hydrocortisone.  Crit Care Med 1998; 26:645-650 Figure 2 and Figure 3, page 727, reproduced with permission from Briegel J, Forst H, Haller M, et al. Stress doses of hydrocortisone reverse hyperdynamic septic shock: A prospective, randomized, double-blind, single-center study.  Crit Care Med  1999; 27:723-732 P = .045 P = .007
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Steroids ,[object Object],[object Object]
Figure 2B, page 867, reproduced with permission from Annane D, S ébille V, Charpentier C,  et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock.  JAMA  2002; 288:862-871
Identification of Relative Adrenal Insufficiency ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Steroids ,[object Object],[object Object],Continue treatments only in nonresponders (rise in cortisol   9   g/dl) Grade E
Dexamethasone and Cortisol Assay
Steroids ,[object Object],[object Object],[object Object]
Steroids ,[object Object],[object Object],[object Object]
Immunologic and Hemodynamic Effects  of “Low-Dose” Hydrocortisone in Septic Shock Figure 3, page 515, reproduced with permission from Keh D, Boehnke T, Weber-Cartens S, et al. Immunologic and hemodynamic effects of “low dose” hydrocortisone in septic shock.  Am J Respir Crit Care Med  2003;167:512-520
Steroids ,[object Object],[object Object],[object Object]
ADRENALS AND SURVIVAL FROM  ENDOTOXEMIA Adapted from Figure 7, page 437, with permission from Witek-Janusek L, Yelich MR. Role of the adrenal cortex and medulla in the young rats’ glucoregulatory response to endotoxin.  Shock  1995; 3:434-439
Steroids ,[object Object],[object Object],Bone, et al.  NEJM 1987; 317-658 VA Systemic Sepsis Cooperative Study Group.  NEJM 1987; 317:659-665
Human Activated Protein C Endogenous Regulator of Coagulation Thrombin Thrombomodulin Protein  C (Inactive) Protein C Activity Blood Vessel Blood Flow   Protein C Receptor Protein S
Results: 28-Day All-Cause Mortality Primary analysis results 2-sided p-value  0.005 Adjusted relative risk reduction  19.4% Increase in odds of survival  38.1% Adapted from Table 4, page 704, with permission from Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis.  N Engl J Med  2001; 344:699-709 35 30 25 20 15 10 5 0 30.8% 24.7% Placebo (n-840) Drotrecogin alfa (activated) (n=850) Mortality (%) 6.1% absolute reduction in mortality
Patient Selection for rhAPC ,[object Object],[object Object],[object Object],[object Object]
Mortality and APACHE II Quartile Adapted from Figure 2, page S90, with permission from Bernard GR. Drotrecogin alfa (activated) (recombinant human activated protein C) for the treatment of severe sepsis.  Crit Care Med  2003; 31[Suppl.]:S85-S90 APACHE II Quartile *Numbers above bars indicate total deaths Mortality (percent) 26:33 57:49 58:48 118:80
Mortality and Numbers of Organs Failing Adapted from Figure 4, page S91, with permission from Bernard GR. Drotrecogin alfa (activated) (recombinant human activated protein C) for the treatment of severe sepsis.  Crit Care Med  2003; 31[Suppl.]:S85-S90 Percent Mortality  0 10 20 30 40 50 60 1 2 3 4 5 Placebo Drotrecogin Number of Organs Failing at Entry
Recombinant Human Activated Protein C (rhAPC) ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Transfusion Strategy in the Critically Ill Figure 2A, page 414, reproduced with permission from Hebert PC, Wells G, Blajchman MA, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care.  N Engl J Med  1999; 340:409-417
Blood Product Administration Red Blood Cells ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Blood Product Administration ,[object Object],[object Object]
Blood Product Administration ,[object Object],[object Object],[object Object],[object Object]
Blood Product Administration ,[object Object],[object Object],Warren et al.  JAMA  2001; 1869-1878
Blood Product Administration ,[object Object],[object Object],[object Object],[object Object],[object Object]
 
Mechanical Ventilation of Sepsis-Induced ALI/ARDS
% Mortality ARDSnet Mechanical Ventilation Protocol Results: Mortality Adapted from Figure 1, page 1306, with permission from The Acute Respiratory Distress Syndrome Network.  N Engl J Med 2000;342:1301-1378
Peak Airway Pressure Inspiratory Plateau Pressure PEEP (5 cm H 2 O 5 0
Mechanical Ventilation of Sepsis-Induced ALI/ARDS ,[object Object],[object Object],[object Object]
Mechanical Ventilation of Sepsis-Induced ALI/ARDS ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
The Role of Prone Positioning in ARDS ,[object Object],[object Object],[object Object],[object Object],[object Object],Gattinoni L, et al.  N Engl J Med  2001;345:568-73; Slutsky AS.  N Engl J Med  2001;345:610-2. Kaplan-Meier estimates of  survival at 6 months Survival (%) 100 75 50 25 0 30 60 90 120 150 180 0 Days Supine group Prone group P=0.65
The Role of Prone Positioning in ARDS ,[object Object],[object Object],[object Object],[object Object]
Mechanical Ventilation of Severe Sepsis ,[object Object],[object Object],[object Object]
Mechanical Ventilation of Septic Patients ,[object Object],[object Object],[object Object],[object Object],[object Object]
Mechanical Ventilation of Septic Patients ,[object Object],[object Object],[object Object]
Prior to SBT ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Sedation and Analgesia in Sepsis ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Neuromuscular Blockers ,[object Object],[object Object],[object Object],[object Object],[object Object]
The Role of Intensive Insulin Therapy in the Critically Ill ,[object Object],Adapted from Figure 1B, page 1363, with permission from van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in critically ill patients.  N Engl J Med  2001;345:1359-67 In-hospital survival (%) 100 0 0 Intensive treatment Conventional treatment Days after admission 80 84 88 92 96 50 100 150 200 250 P=0.01
Glucose Control ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Renal Replacement ,[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],Bicarbonate Therapy
Changing pH Has Limited Value Treatment Before After NaHCO3 (2 mEq/kg) pH 7.22 7.36 PAOP 15 17 Cardiac output 6.7 7.5 0.9% NaCl pH 7.24 7.23 PAOP 14 17 Cardiac output 6.6 7.3 Cooper DJ, et al.  Ann Intern Med 1990; 112:492-498
Deep Vein Thrombosis Prophylaxis ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Primary Stress Ulcer Risk Factors Frequently Present in Severe Sepsis ,[object Object],[object Object],[object Object]
Choice of Agents for Stress Ulcer Prophylaxis ,[object Object],[object Object],[object Object],Cook DJ, et al.  Am J Med  1991; 91:519-527
Consideration for Limitation of Support ,[object Object],[object Object]
Phase 1  Barcelona declaration Phase 2  Evidence based guidelines Paediatric issues Phase 3  Implementation and education Surviving Sepsis
Fluid Resuscitation ,[object Object],[object Object],[object Object]
Hemodynamic Support ,[object Object],[object Object],[object Object],[object Object],[object Object]
Therapeutic Endpoints ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Other Therapies ,[object Object],[object Object],[object Object],[object Object]
Phase 1  Barcelona declaration Phase 2  Evidence based guideline Phase 3 Implementation and education Surviving Sepsis
Sepsis Resuscitation Bundle ,[object Object],[object Object],[object Object]
Sepsis Resuscitation Bundle ,[object Object],[object Object],[object Object],*See the individual chart measurement tool for an equivalency chart.
Sepsis Management Bundle ,[object Object],[object Object],*See the individual chart measurement tool for an equivalency chart.
Sepsis Management Bundle ,[object Object],[object Object]
Sepsis Resuscitation Bundle ,[object Object],[object Object],[object Object],**Achieving a mixed venous oxygen saturation (SvO 2 ) of 65% is an acceptable alternative.
A clinician, armed with the sepsis bundles, attacks the three heads of severe sepsis: hypotension, hypoperfusion and organ dysfunction.  Crit Care Med  2004; 320(Suppl):S595-S597
Actual title of painting is “Hercules Kills Cerberus,” by Renato Pettinato, 2001. Painting hangs in Zuccaro Place in Agira, Sicily, Italy.  Used with permission of artist and the Rubolotto family.
www.survivingsepsis.org   www.IHI.org
Acknowledgment The SSC is grateful to R. Phillip Dellinger, MD, for his input into creation of this slide kit.

Mais conteúdo relacionado

Mais procurados

Fluid responsiveness in critically ill patients
Fluid responsiveness in critically ill patientsFluid responsiveness in critically ill patients
Fluid responsiveness in critically ill patientsUbaidur Rahaman
 
Sepsis and septic shock guidelines 2021. part 1
Sepsis and septic shock guidelines 2021. part 1Sepsis and septic shock guidelines 2021. part 1
Sepsis and septic shock guidelines 2021. part 1MEEQAT HOSPITAL
 
initial assessment of critically ill patients(PRESENTED AT IMA HOUSE,CUTTACK)
initial assessment of critically ill patients(PRESENTED AT IMA HOUSE,CUTTACK)initial assessment of critically ill patients(PRESENTED AT IMA HOUSE,CUTTACK)
initial assessment of critically ill patients(PRESENTED AT IMA HOUSE,CUTTACK)Prerna Biswal
 
Surviving sepsis compaign (adults) Guidelines updates 2021. “Long Term Outcom...
Surviving sepsis compaign (adults)Guidelines updates 2021.“Long Term Outcom...Surviving sepsis compaign (adults)Guidelines updates 2021.“Long Term Outcom...
Surviving sepsis compaign (adults) Guidelines updates 2021. “Long Term Outcom...MEEQAT HOSPITAL
 
Landmark Critical Care Clinical Trials
Landmark Critical Care Clinical TrialsLandmark Critical Care Clinical Trials
Landmark Critical Care Clinical TrialsSherif Elbadrawy
 
Sepsis – pathophysiology and management
Sepsis – pathophysiology and managementSepsis – pathophysiology and management
Sepsis – pathophysiology and managementVidhi Singh
 
Shock & its management
Shock & its managementShock & its management
Shock & its managementBalraj Shukla
 
Fluid management in ICU
Fluid management in ICUFluid management in ICU
Fluid management in ICUAhmed Elsaid
 
sepsis SSC 2021 Updates Ventilation and additional therapy
sepsis SSC 2021 Updates Ventilation and additional therapysepsis SSC 2021 Updates Ventilation and additional therapy
sepsis SSC 2021 Updates Ventilation and additional therapyMEEQAT HOSPITAL
 
Surviving Sepsis Campaign 2021 guidelines.pptx
Surviving Sepsis Campaign 2021 guidelines.pptxSurviving Sepsis Campaign 2021 guidelines.pptx
Surviving Sepsis Campaign 2021 guidelines.pptxRabindra Tamang
 
Resuscitation Fluids
Resuscitation FluidsResuscitation Fluids
Resuscitation FluidsSun Yai-Cheng
 
Case triple vessel disease
Case triple vessel diseaseCase triple vessel disease
Case triple vessel diseaseDipesh Tamrakar
 
Post Cardiac Arrest Syndrome
Post Cardiac Arrest SyndromePost Cardiac Arrest Syndrome
Post Cardiac Arrest SyndromeSun Yai-Cheng
 
Renal Replacement Therapy: modes and evidence
Renal Replacement Therapy: modes and evidenceRenal Replacement Therapy: modes and evidence
Renal Replacement Therapy: modes and evidenceMohd Saif Khan
 

Mais procurados (20)

Sepsis and septic shock
Sepsis  and septic shockSepsis  and septic shock
Sepsis and septic shock
 
Fluid responsiveness in critically ill patients
Fluid responsiveness in critically ill patientsFluid responsiveness in critically ill patients
Fluid responsiveness in critically ill patients
 
Sepsis and septic shock guidelines 2021. part 1
Sepsis and septic shock guidelines 2021. part 1Sepsis and septic shock guidelines 2021. part 1
Sepsis and septic shock guidelines 2021. part 1
 
Sepsis
SepsisSepsis
Sepsis
 
Cardiogenic shock dr awadhesh
Cardiogenic shock  dr awadheshCardiogenic shock  dr awadhesh
Cardiogenic shock dr awadhesh
 
initial assessment of critically ill patients(PRESENTED AT IMA HOUSE,CUTTACK)
initial assessment of critically ill patients(PRESENTED AT IMA HOUSE,CUTTACK)initial assessment of critically ill patients(PRESENTED AT IMA HOUSE,CUTTACK)
initial assessment of critically ill patients(PRESENTED AT IMA HOUSE,CUTTACK)
 
Surviving sepsis compaign (adults) Guidelines updates 2021. “Long Term Outcom...
Surviving sepsis compaign (adults)Guidelines updates 2021.“Long Term Outcom...Surviving sepsis compaign (adults)Guidelines updates 2021.“Long Term Outcom...
Surviving sepsis compaign (adults) Guidelines updates 2021. “Long Term Outcom...
 
Landmark Critical Care Clinical Trials
Landmark Critical Care Clinical TrialsLandmark Critical Care Clinical Trials
Landmark Critical Care Clinical Trials
 
Sepsis – pathophysiology and management
Sepsis – pathophysiology and managementSepsis – pathophysiology and management
Sepsis – pathophysiology and management
 
Shock & its management
Shock & its managementShock & its management
Shock & its management
 
Fluid management in ICU
Fluid management in ICUFluid management in ICU
Fluid management in ICU
 
sepsis SSC 2021 Updates Ventilation and additional therapy
sepsis SSC 2021 Updates Ventilation and additional therapysepsis SSC 2021 Updates Ventilation and additional therapy
sepsis SSC 2021 Updates Ventilation and additional therapy
 
Surviving Sepsis Campaign 2021 guidelines.pptx
Surviving Sepsis Campaign 2021 guidelines.pptxSurviving Sepsis Campaign 2021 guidelines.pptx
Surviving Sepsis Campaign 2021 guidelines.pptx
 
Sepsis
SepsisSepsis
Sepsis
 
Sepsis
SepsisSepsis
Sepsis
 
Septic shock
Septic shockSeptic shock
Septic shock
 
Resuscitation Fluids
Resuscitation FluidsResuscitation Fluids
Resuscitation Fluids
 
Case triple vessel disease
Case triple vessel diseaseCase triple vessel disease
Case triple vessel disease
 
Post Cardiac Arrest Syndrome
Post Cardiac Arrest SyndromePost Cardiac Arrest Syndrome
Post Cardiac Arrest Syndrome
 
Renal Replacement Therapy: modes and evidence
Renal Replacement Therapy: modes and evidenceRenal Replacement Therapy: modes and evidence
Renal Replacement Therapy: modes and evidence
 

Destaque

Septicemia/Sepsis Slides
Septicemia/Sepsis SlidesSepticemia/Sepsis Slides
Septicemia/Sepsis SlidesKatrishia Velez
 
Turkey 2015
Turkey 2015Turkey 2015
Turkey 2015tyfngnc
 
New definition of sepsis... sepsis 3
New definition of sepsis... sepsis 3New definition of sepsis... sepsis 3
New definition of sepsis... sepsis 3Neisevilie Nisa
 
Acute and critical care, IN NURSING, MANAGEMENT OF CLIENT IN ICU.
Acute and critical care, IN NURSING, MANAGEMENT OF CLIENT IN ICU.Acute and critical care, IN NURSING, MANAGEMENT OF CLIENT IN ICU.
Acute and critical care, IN NURSING, MANAGEMENT OF CLIENT IN ICU.dharmendra raval
 
Lec # 3, assessment of ci pt
Lec # 3, assessment of ci ptLec # 3, assessment of ci pt
Lec # 3, assessment of ci ptAli Sheikh
 
Computerised real time automatic SAPS APACHE and SOFA score calculation and d...
Computerised real time automatic SAPS APACHE and SOFA score calculation and d...Computerised real time automatic SAPS APACHE and SOFA score calculation and d...
Computerised real time automatic SAPS APACHE and SOFA score calculation and d...All India Institute of Medical Sciences
 
Structured Approach to Critically Ill and Injured Patient
Structured Approach to Critically Ill and Injured PatientStructured Approach to Critically Ill and Injured Patient
Structured Approach to Critically Ill and Injured Patientmetriccertain
 
Care of critical ill patient
Care of critical ill patientCare of critical ill patient
Care of critical ill patientEunice Abdulai
 
Care of the critically ill patient student
Care of the critically ill patient studentCare of the critically ill patient student
Care of the critically ill patient studentJocelyn Ludlow MN RN
 
Intensive care services
Intensive care servicesIntensive care services
Intensive care servicesNc Das
 
Critical care nursing concept
Critical  care  nursing  conceptCritical  care  nursing  concept
Critical care nursing conceptNil shadow
 
Sepsis updates 2016
Sepsis updates 2016Sepsis updates 2016
Sepsis updates 2016Ashraf Nadim
 
Glasgow Coma Scale Presentation
Glasgow Coma Scale PresentationGlasgow Coma Scale Presentation
Glasgow Coma Scale PresentationHayden G
 

Destaque (16)

Septicemia/Sepsis Slides
Septicemia/Sepsis SlidesSepticemia/Sepsis Slides
Septicemia/Sepsis Slides
 
Turkey 2015
Turkey 2015Turkey 2015
Turkey 2015
 
New definition of sepsis... sepsis 3
New definition of sepsis... sepsis 3New definition of sepsis... sepsis 3
New definition of sepsis... sepsis 3
 
Acute and critical care, IN NURSING, MANAGEMENT OF CLIENT IN ICU.
Acute and critical care, IN NURSING, MANAGEMENT OF CLIENT IN ICU.Acute and critical care, IN NURSING, MANAGEMENT OF CLIENT IN ICU.
Acute and critical care, IN NURSING, MANAGEMENT OF CLIENT IN ICU.
 
Lec # 3, assessment of ci pt
Lec # 3, assessment of ci ptLec # 3, assessment of ci pt
Lec # 3, assessment of ci pt
 
Intensive care Units Role of Nursing
Intensive care Units Role of Nursing Intensive care Units Role of Nursing
Intensive care Units Role of Nursing
 
Computerised real time automatic SAPS APACHE and SOFA score calculation and d...
Computerised real time automatic SAPS APACHE and SOFA score calculation and d...Computerised real time automatic SAPS APACHE and SOFA score calculation and d...
Computerised real time automatic SAPS APACHE and SOFA score calculation and d...
 
Structured approach for critically ill patient
Structured approach for critically ill patient Structured approach for critically ill patient
Structured approach for critically ill patient
 
Structured Approach to Critically Ill and Injured Patient
Structured Approach to Critically Ill and Injured PatientStructured Approach to Critically Ill and Injured Patient
Structured Approach to Critically Ill and Injured Patient
 
Care of critical ill patient
Care of critical ill patientCare of critical ill patient
Care of critical ill patient
 
Care of the critically ill patient student
Care of the critically ill patient studentCare of the critically ill patient student
Care of the critically ill patient student
 
Intensive care services
Intensive care servicesIntensive care services
Intensive care services
 
Critical care nursing concept
Critical  care  nursing  conceptCritical  care  nursing  concept
Critical care nursing concept
 
1. critical care
1.  critical care1.  critical care
1. critical care
 
Sepsis updates 2016
Sepsis updates 2016Sepsis updates 2016
Sepsis updates 2016
 
Glasgow Coma Scale Presentation
Glasgow Coma Scale PresentationGlasgow Coma Scale Presentation
Glasgow Coma Scale Presentation
 

Semelhante a Guidelines Sepsis(Power Point)

Severe Sepsis & Septic Shock
Severe Sepsis & Septic ShockSevere Sepsis & Septic Shock
Severe Sepsis & Septic ShockAndrew Ferguson
 
Optimzing sepsis management
Optimzing sepsis managementOptimzing sepsis management
Optimzing sepsis managementEM OMSB
 
Jeff_Pulm_CC__grand_rounds_2011.ppt
Jeff_Pulm_CC__grand_rounds_2011.pptJeff_Pulm_CC__grand_rounds_2011.ppt
Jeff_Pulm_CC__grand_rounds_2011.pptdrram666
 
Venous Thromboembolism (VTE): Recent Advances in Reducing the Disease Burden
Venous Thromboembolism (VTE): Recent Advances in Reducing the Disease BurdenVenous Thromboembolism (VTE): Recent Advances in Reducing the Disease Burden
Venous Thromboembolism (VTE): Recent Advances in Reducing the Disease BurdenNBCA
 
Septic cardiomyopathy colour
Septic cardiomyopathy   colourSeptic cardiomyopathy   colour
Septic cardiomyopathy colourPalepu BN Gopal
 
Sepsisgrandrounds
SepsisgrandroundsSepsisgrandrounds
Sepsisgrandroundstomnugent
 
HF_Managing CHF with beta blcokers in the the era of ARNI.pptx
HF_Managing CHF with beta blcokers in the the era of ARNI.pptxHF_Managing CHF with beta blcokers in the the era of ARNI.pptx
HF_Managing CHF with beta blcokers in the the era of ARNI.pptxJEEWANKUMAR14
 
Sepsis modern day killer
Sepsis modern day killerSepsis modern day killer
Sepsis modern day killerPrashant Nasa
 
sepsis 2019.pdf
sepsis 2019.pdfsepsis 2019.pdf
sepsis 2019.pdfzahid aziz
 
Journal Club By Dr. Gadeppa 1.pptx
Journal Club By Dr. Gadeppa 1.pptxJournal Club By Dr. Gadeppa 1.pptx
Journal Club By Dr. Gadeppa 1.pptxGadeppa H
 
shock marker
shock markershock marker
shock markerEM OMSB
 
Serelaxin in acute heart failure
Serelaxin in acute heart failureSerelaxin in acute heart failure
Serelaxin in acute heart failuredrucsamal
 

Semelhante a Guidelines Sepsis(Power Point) (20)

Sepsis guidlines
Sepsis guidlinesSepsis guidlines
Sepsis guidlines
 
Severe Sepsis & Septic Shock
Severe Sepsis & Septic ShockSevere Sepsis & Septic Shock
Severe Sepsis & Septic Shock
 
Optimzing sepsis management
Optimzing sepsis managementOptimzing sepsis management
Optimzing sepsis management
 
Jeff_Pulm_CC__grand_rounds_2011.ppt
Jeff_Pulm_CC__grand_rounds_2011.pptJeff_Pulm_CC__grand_rounds_2011.ppt
Jeff_Pulm_CC__grand_rounds_2011.ppt
 
Sepsis 9-2015
Sepsis  9-2015Sepsis  9-2015
Sepsis 9-2015
 
Venous Thromboembolism (VTE): Recent Advances in Reducing the Disease Burden
Venous Thromboembolism (VTE): Recent Advances in Reducing the Disease BurdenVenous Thromboembolism (VTE): Recent Advances in Reducing the Disease Burden
Venous Thromboembolism (VTE): Recent Advances in Reducing the Disease Burden
 
Ards guidelines john
Ards guidelines   johnArds guidelines   john
Ards guidelines john
 
Septic cardiomyopathy colour
Septic cardiomyopathy   colourSeptic cardiomyopathy   colour
Septic cardiomyopathy colour
 
Sepsisgrandrounds
SepsisgrandroundsSepsisgrandrounds
Sepsisgrandrounds
 
HF_Managing CHF with beta blcokers in the the era of ARNI.pptx
HF_Managing CHF with beta blcokers in the the era of ARNI.pptxHF_Managing CHF with beta blcokers in the the era of ARNI.pptx
HF_Managing CHF with beta blcokers in the the era of ARNI.pptx
 
Sirs present
Sirs presentSirs present
Sirs present
 
Sepsis modern day killer
Sepsis modern day killerSepsis modern day killer
Sepsis modern day killer
 
Sirt oslo 1_feb2018
Sirt oslo 1_feb2018Sirt oslo 1_feb2018
Sirt oslo 1_feb2018
 
Acute Heart Failure
Acute Heart FailureAcute Heart Failure
Acute Heart Failure
 
sepsis 2019.pdf
sepsis 2019.pdfsepsis 2019.pdf
sepsis 2019.pdf
 
Journal Club By Dr. Gadeppa 1.pptx
Journal Club By Dr. Gadeppa 1.pptxJournal Club By Dr. Gadeppa 1.pptx
Journal Club By Dr. Gadeppa 1.pptx
 
shock marker
shock markershock marker
shock marker
 
Sepsis
SepsisSepsis
Sepsis
 
Serelaxin in acute heart failure
Serelaxin in acute heart failureSerelaxin in acute heart failure
Serelaxin in acute heart failure
 
Section21
Section21Section21
Section21
 

Último

Top Quality Call Girl Service Kalyanpur 6378878445 Available Call Girls Any Time
Top Quality Call Girl Service Kalyanpur 6378878445 Available Call Girls Any TimeTop Quality Call Girl Service Kalyanpur 6378878445 Available Call Girls Any Time
Top Quality Call Girl Service Kalyanpur 6378878445 Available Call Girls Any TimeCall Girls Delhi
 
Lucknow Call girls - 8800925952 - 24x7 service with hotel room
Lucknow Call girls - 8800925952 - 24x7 service with hotel roomLucknow Call girls - 8800925952 - 24x7 service with hotel room
Lucknow Call girls - 8800925952 - 24x7 service with hotel roomdiscovermytutordmt
 
Night 7k to 12k Navi Mumbai Call Girl Photo 👉 BOOK NOW 9833363713 👈 ♀️ night ...
Night 7k to 12k Navi Mumbai Call Girl Photo 👉 BOOK NOW 9833363713 👈 ♀️ night ...Night 7k to 12k Navi Mumbai Call Girl Photo 👉 BOOK NOW 9833363713 👈 ♀️ night ...
Night 7k to 12k Navi Mumbai Call Girl Photo 👉 BOOK NOW 9833363713 👈 ♀️ night ...aartirawatdelhi
 
The Most Attractive Hyderabad Call Girls Kothapet 𖠋 6297143586 𖠋 Will You Mis...
The Most Attractive Hyderabad Call Girls Kothapet 𖠋 6297143586 𖠋 Will You Mis...The Most Attractive Hyderabad Call Girls Kothapet 𖠋 6297143586 𖠋 Will You Mis...
The Most Attractive Hyderabad Call Girls Kothapet 𖠋 6297143586 𖠋 Will You Mis...chandars293
 
Call Girls Ludhiana Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Ludhiana Just Call 9907093804 Top Class Call Girl Service AvailableCall Girls Ludhiana Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Ludhiana Just Call 9907093804 Top Class Call Girl Service AvailableDipal Arora
 
Call Girls Faridabad Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Faridabad Just Call 9907093804 Top Class Call Girl Service AvailableCall Girls Faridabad Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Faridabad Just Call 9907093804 Top Class Call Girl Service AvailableDipal Arora
 
Call Girls Ooty Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Ooty Just Call 9907093804 Top Class Call Girl Service AvailableCall Girls Ooty Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Ooty Just Call 9907093804 Top Class Call Girl Service AvailableDipal Arora
 
Call Girls Tirupati Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Tirupati Just Call 9907093804 Top Class Call Girl Service AvailableCall Girls Tirupati Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Tirupati Just Call 9907093804 Top Class Call Girl Service AvailableDipal Arora
 
Call Girls Nagpur Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Nagpur Just Call 9907093804 Top Class Call Girl Service AvailableCall Girls Nagpur Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Nagpur Just Call 9907093804 Top Class Call Girl Service AvailableDipal Arora
 
Top Rated Bangalore Call Girls Mg Road ⟟ 9332606886 ⟟ Call Me For Genuine S...
Top Rated Bangalore Call Girls Mg Road ⟟   9332606886 ⟟ Call Me For Genuine S...Top Rated Bangalore Call Girls Mg Road ⟟   9332606886 ⟟ Call Me For Genuine S...
Top Rated Bangalore Call Girls Mg Road ⟟ 9332606886 ⟟ Call Me For Genuine S...narwatsonia7
 
Call Girls Cuttack Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Cuttack Just Call 9907093804 Top Class Call Girl Service AvailableCall Girls Cuttack Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Cuttack Just Call 9907093804 Top Class Call Girl Service AvailableDipal Arora
 
Call Girls Bhubaneswar Just Call 9907093804 Top Class Call Girl Service Avail...
Call Girls Bhubaneswar Just Call 9907093804 Top Class Call Girl Service Avail...Call Girls Bhubaneswar Just Call 9907093804 Top Class Call Girl Service Avail...
Call Girls Bhubaneswar Just Call 9907093804 Top Class Call Girl Service Avail...Dipal Arora
 
♛VVIP Hyderabad Call Girls Chintalkunta🖕7001035870🖕Riya Kappor Top Call Girl ...
♛VVIP Hyderabad Call Girls Chintalkunta🖕7001035870🖕Riya Kappor Top Call Girl ...♛VVIP Hyderabad Call Girls Chintalkunta🖕7001035870🖕Riya Kappor Top Call Girl ...
♛VVIP Hyderabad Call Girls Chintalkunta🖕7001035870🖕Riya Kappor Top Call Girl ...astropune
 
Call Girls Siliguri Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Siliguri Just Call 9907093804 Top Class Call Girl Service AvailableCall Girls Siliguri Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Siliguri Just Call 9907093804 Top Class Call Girl Service AvailableDipal Arora
 
Bangalore Call Girls Nelamangala Number 9332606886 Meetin With Bangalore Esc...
Bangalore Call Girls Nelamangala Number 9332606886  Meetin With Bangalore Esc...Bangalore Call Girls Nelamangala Number 9332606886  Meetin With Bangalore Esc...
Bangalore Call Girls Nelamangala Number 9332606886 Meetin With Bangalore Esc...narwatsonia7
 
Best Rate (Patna ) Call Girls Patna ⟟ 8617370543 ⟟ High Class Call Girl In 5 ...
Best Rate (Patna ) Call Girls Patna ⟟ 8617370543 ⟟ High Class Call Girl In 5 ...Best Rate (Patna ) Call Girls Patna ⟟ 8617370543 ⟟ High Class Call Girl In 5 ...
Best Rate (Patna ) Call Girls Patna ⟟ 8617370543 ⟟ High Class Call Girl In 5 ...Dipal Arora
 
Best Rate (Hyderabad) Call Girls Jahanuma ⟟ 8250192130 ⟟ High Class Call Girl...
Best Rate (Hyderabad) Call Girls Jahanuma ⟟ 8250192130 ⟟ High Class Call Girl...Best Rate (Hyderabad) Call Girls Jahanuma ⟟ 8250192130 ⟟ High Class Call Girl...
Best Rate (Hyderabad) Call Girls Jahanuma ⟟ 8250192130 ⟟ High Class Call Girl...astropune
 
Call Girls Varanasi Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Varanasi Just Call 9907093804 Top Class Call Girl Service AvailableCall Girls Varanasi Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Varanasi Just Call 9907093804 Top Class Call Girl Service AvailableDipal Arora
 
(Low Rate RASHMI ) Rate Of Call Girls Jaipur ❣ 8445551418 ❣ Elite Models & Ce...
(Low Rate RASHMI ) Rate Of Call Girls Jaipur ❣ 8445551418 ❣ Elite Models & Ce...(Low Rate RASHMI ) Rate Of Call Girls Jaipur ❣ 8445551418 ❣ Elite Models & Ce...
(Low Rate RASHMI ) Rate Of Call Girls Jaipur ❣ 8445551418 ❣ Elite Models & Ce...parulsinha
 
Book Paid Powai Call Girls Mumbai 𖠋 9930245274 𖠋Low Budget Full Independent H...
Book Paid Powai Call Girls Mumbai 𖠋 9930245274 𖠋Low Budget Full Independent H...Book Paid Powai Call Girls Mumbai 𖠋 9930245274 𖠋Low Budget Full Independent H...
Book Paid Powai Call Girls Mumbai 𖠋 9930245274 𖠋Low Budget Full Independent H...Call Girls in Nagpur High Profile
 

Último (20)

Top Quality Call Girl Service Kalyanpur 6378878445 Available Call Girls Any Time
Top Quality Call Girl Service Kalyanpur 6378878445 Available Call Girls Any TimeTop Quality Call Girl Service Kalyanpur 6378878445 Available Call Girls Any Time
Top Quality Call Girl Service Kalyanpur 6378878445 Available Call Girls Any Time
 
Lucknow Call girls - 8800925952 - 24x7 service with hotel room
Lucknow Call girls - 8800925952 - 24x7 service with hotel roomLucknow Call girls - 8800925952 - 24x7 service with hotel room
Lucknow Call girls - 8800925952 - 24x7 service with hotel room
 
Night 7k to 12k Navi Mumbai Call Girl Photo 👉 BOOK NOW 9833363713 👈 ♀️ night ...
Night 7k to 12k Navi Mumbai Call Girl Photo 👉 BOOK NOW 9833363713 👈 ♀️ night ...Night 7k to 12k Navi Mumbai Call Girl Photo 👉 BOOK NOW 9833363713 👈 ♀️ night ...
Night 7k to 12k Navi Mumbai Call Girl Photo 👉 BOOK NOW 9833363713 👈 ♀️ night ...
 
The Most Attractive Hyderabad Call Girls Kothapet 𖠋 6297143586 𖠋 Will You Mis...
The Most Attractive Hyderabad Call Girls Kothapet 𖠋 6297143586 𖠋 Will You Mis...The Most Attractive Hyderabad Call Girls Kothapet 𖠋 6297143586 𖠋 Will You Mis...
The Most Attractive Hyderabad Call Girls Kothapet 𖠋 6297143586 𖠋 Will You Mis...
 
Call Girls Ludhiana Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Ludhiana Just Call 9907093804 Top Class Call Girl Service AvailableCall Girls Ludhiana Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Ludhiana Just Call 9907093804 Top Class Call Girl Service Available
 
Call Girls Faridabad Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Faridabad Just Call 9907093804 Top Class Call Girl Service AvailableCall Girls Faridabad Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Faridabad Just Call 9907093804 Top Class Call Girl Service Available
 
Call Girls Ooty Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Ooty Just Call 9907093804 Top Class Call Girl Service AvailableCall Girls Ooty Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Ooty Just Call 9907093804 Top Class Call Girl Service Available
 
Call Girls Tirupati Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Tirupati Just Call 9907093804 Top Class Call Girl Service AvailableCall Girls Tirupati Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Tirupati Just Call 9907093804 Top Class Call Girl Service Available
 
Call Girls Nagpur Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Nagpur Just Call 9907093804 Top Class Call Girl Service AvailableCall Girls Nagpur Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Nagpur Just Call 9907093804 Top Class Call Girl Service Available
 
Top Rated Bangalore Call Girls Mg Road ⟟ 9332606886 ⟟ Call Me For Genuine S...
Top Rated Bangalore Call Girls Mg Road ⟟   9332606886 ⟟ Call Me For Genuine S...Top Rated Bangalore Call Girls Mg Road ⟟   9332606886 ⟟ Call Me For Genuine S...
Top Rated Bangalore Call Girls Mg Road ⟟ 9332606886 ⟟ Call Me For Genuine S...
 
Call Girls Cuttack Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Cuttack Just Call 9907093804 Top Class Call Girl Service AvailableCall Girls Cuttack Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Cuttack Just Call 9907093804 Top Class Call Girl Service Available
 
Call Girls Bhubaneswar Just Call 9907093804 Top Class Call Girl Service Avail...
Call Girls Bhubaneswar Just Call 9907093804 Top Class Call Girl Service Avail...Call Girls Bhubaneswar Just Call 9907093804 Top Class Call Girl Service Avail...
Call Girls Bhubaneswar Just Call 9907093804 Top Class Call Girl Service Avail...
 
♛VVIP Hyderabad Call Girls Chintalkunta🖕7001035870🖕Riya Kappor Top Call Girl ...
♛VVIP Hyderabad Call Girls Chintalkunta🖕7001035870🖕Riya Kappor Top Call Girl ...♛VVIP Hyderabad Call Girls Chintalkunta🖕7001035870🖕Riya Kappor Top Call Girl ...
♛VVIP Hyderabad Call Girls Chintalkunta🖕7001035870🖕Riya Kappor Top Call Girl ...
 
Call Girls Siliguri Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Siliguri Just Call 9907093804 Top Class Call Girl Service AvailableCall Girls Siliguri Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Siliguri Just Call 9907093804 Top Class Call Girl Service Available
 
Bangalore Call Girls Nelamangala Number 9332606886 Meetin With Bangalore Esc...
Bangalore Call Girls Nelamangala Number 9332606886  Meetin With Bangalore Esc...Bangalore Call Girls Nelamangala Number 9332606886  Meetin With Bangalore Esc...
Bangalore Call Girls Nelamangala Number 9332606886 Meetin With Bangalore Esc...
 
Best Rate (Patna ) Call Girls Patna ⟟ 8617370543 ⟟ High Class Call Girl In 5 ...
Best Rate (Patna ) Call Girls Patna ⟟ 8617370543 ⟟ High Class Call Girl In 5 ...Best Rate (Patna ) Call Girls Patna ⟟ 8617370543 ⟟ High Class Call Girl In 5 ...
Best Rate (Patna ) Call Girls Patna ⟟ 8617370543 ⟟ High Class Call Girl In 5 ...
 
Best Rate (Hyderabad) Call Girls Jahanuma ⟟ 8250192130 ⟟ High Class Call Girl...
Best Rate (Hyderabad) Call Girls Jahanuma ⟟ 8250192130 ⟟ High Class Call Girl...Best Rate (Hyderabad) Call Girls Jahanuma ⟟ 8250192130 ⟟ High Class Call Girl...
Best Rate (Hyderabad) Call Girls Jahanuma ⟟ 8250192130 ⟟ High Class Call Girl...
 
Call Girls Varanasi Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Varanasi Just Call 9907093804 Top Class Call Girl Service AvailableCall Girls Varanasi Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Varanasi Just Call 9907093804 Top Class Call Girl Service Available
 
(Low Rate RASHMI ) Rate Of Call Girls Jaipur ❣ 8445551418 ❣ Elite Models & Ce...
(Low Rate RASHMI ) Rate Of Call Girls Jaipur ❣ 8445551418 ❣ Elite Models & Ce...(Low Rate RASHMI ) Rate Of Call Girls Jaipur ❣ 8445551418 ❣ Elite Models & Ce...
(Low Rate RASHMI ) Rate Of Call Girls Jaipur ❣ 8445551418 ❣ Elite Models & Ce...
 
Book Paid Powai Call Girls Mumbai 𖠋 9930245274 𖠋Low Budget Full Independent H...
Book Paid Powai Call Girls Mumbai 𖠋 9930245274 𖠋Low Budget Full Independent H...Book Paid Powai Call Girls Mumbai 𖠋 9930245274 𖠋Low Budget Full Independent H...
Book Paid Powai Call Girls Mumbai 𖠋 9930245274 𖠋Low Budget Full Independent H...
 

Guidelines Sepsis(Power Point)

  • 1. Surviving Sepsis Campaign Guidelines for Management of Severe Sepsis/Septic Shock An Overview
  • 2. Surviving Sepsis A global program to: Reduce mortality rates in severe sepsis
  • 3. Phase 1 Barcelona declaration Phase 2 Evidence based guidelines Phase 3 Implementation and education Surviving Sepsis
  • 4. Phase 1 Barcelona declaration Phase 2 Evidence based guidelines Phase 3 Implementation and education Surviving Sepsis
  • 5.
  • 6.
  • 7. Surviving Sepsis Campaign (SSC) Guidelines for Management of Severe Sepsis and Septic Shock Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, Gea-Banacloche J, Keh D, Marshall JC, Parker MM, Ramsay G, Zimmerman JL, Vincent JL, Levy MM and the SSC Management Guidelines Committee Crit Care Med 2004;32:858-873 Intensive Care Med 2004;30:536-555 available online at www.springerlink.com www.sccm.org www.sepsisforum.com
  • 8. Sackett DL. Chest 1989; 95:2S–4S Sprung CL, Bernard GR, Dellinger RP. Intensive Care Medicine 2001; 27(Suppl):S1-S2
  • 9.
  • 11. Figure B, page 948, reproduced with permission from Dellinger RP. Cardiovascular management of septic shock. Crit Care Med 2003;31:946-955.
  • 12. The Importance of Early Goal-Directed Therapy for Sepsis Induced Hypoperfusion Adapted from Table 3, page 1374, with permission from Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001; 345:1368-1377 In-hospital mortality (all patients) 0 10 20 30 40 50 60 Standard therapy EGDT 28-day mortality 60-day mortality NNT to prevent 1 event (death) = 6-8 Mortality (%)
  • 13.
  • 14. Adapted from Table 4, page 2731, with permission from LeDoux, Astiz ME, Carpati CM, Rackow ED. Effects of perfusion pressure on tissue perfusion in septic shock. Crit Care Med 2000; 28:2729-2732 MAP Urinary output (mL) 49 + 18 56 + 21 43 + 13 .60/.71 Capillary blood flow (mL/min/100 g) 6.0 + 1.6 5.8 + 11 5.3 + 0.9 .59/.55 Red Cell Velocity (au) 0.42 + 0.06 0.44 + 016 0.42 + 0.06 .74/.97 Pico 2 (mm Hg) 41 + 2 47 + 2 46 + 2 .11/.12 Pa-Pico 2 (mm Hg) 13 + 3 17 + 3 16 + 3 .27/.40 75 mm Hg 65 mm Hg 85 mm Hg F/LT
  • 15.
  • 16.
  • 17.
  • 18.
  • 19.
  • 20.
  • 21.
  • 22. Photograph used with permission from Janice L. Zimmerman, MD
  • 23. EKG tracing reproduced with permission from Janice L. Zimmerman, MD
  • 24.
  • 25. Figure 2, page 206, reproduced with permission from Choi PT, Yip G, Quinonez L, Cook DJ. Crystalloids vs. colloids in fluid resuscitation: A systematic review. Crit Care Med 1999; 27:200–210
  • 26.
  • 27.
  • 28. Effects of Dopamine, Norepinephrine, and Epinephrine on the Splanchnic Circulation in Septic Shock Figure 2, page 1665, reproduced with permission from De Backer D, Creteur J, Silva E, Vincent JL. Effects of dopamine, norepinephrine, and epinephrine on the splanchnic circulation in septic shock: Which is best? Crit Care Med 2003; 31:1659-1667
  • 29.
  • 30.
  • 31. Circulating Vasopressin Levels in Septic Shock Figure 2, page 1755 reproduced with permission from Sharshar T, Blanchard A, Paillard M, et al. Circulating vasopressin levels in septic shock. Crit Care Med 2003; 31:1752-1758
  • 32.
  • 33.
  • 34. During Septic Shock Images used with permission from Joseph E. Parrillo, MD 10 Days Post Shock Diastole Systole Diastole Systole
  • 35.
  • 36.
  • 37. Figure 2A, page 867, reproduced with permission from Annane D, S ébille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002; 288:862-871 Steroid Therapy
  • 38. Figure 2 and Figure 3, page 648, reproduced with permission from Bollaert PE, Charpentier C, Levy B, et al. Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit Care Med 1998; 26:645-650 Figure 2 and Figure 3, page 727, reproduced with permission from Briegel J, Forst H, Haller M, et al. Stress doses of hydrocortisone reverse hyperdynamic septic shock: A prospective, randomized, double-blind, single-center study. Crit Care Med 1999; 27:723-732 P = .045 P = .007
  • 39.
  • 40.
  • 41. Figure 2B, page 867, reproduced with permission from Annane D, S ébille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002; 288:862-871
  • 42.
  • 43.
  • 45.
  • 46.
  • 47. Immunologic and Hemodynamic Effects of “Low-Dose” Hydrocortisone in Septic Shock Figure 3, page 515, reproduced with permission from Keh D, Boehnke T, Weber-Cartens S, et al. Immunologic and hemodynamic effects of “low dose” hydrocortisone in septic shock. Am J Respir Crit Care Med 2003;167:512-520
  • 48.
  • 49. ADRENALS AND SURVIVAL FROM ENDOTOXEMIA Adapted from Figure 7, page 437, with permission from Witek-Janusek L, Yelich MR. Role of the adrenal cortex and medulla in the young rats’ glucoregulatory response to endotoxin. Shock 1995; 3:434-439
  • 50.
  • 51. Human Activated Protein C Endogenous Regulator of Coagulation Thrombin Thrombomodulin Protein C (Inactive) Protein C Activity Blood Vessel Blood Flow  Protein C Receptor Protein S
  • 52. Results: 28-Day All-Cause Mortality Primary analysis results 2-sided p-value 0.005 Adjusted relative risk reduction 19.4% Increase in odds of survival 38.1% Adapted from Table 4, page 704, with permission from Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699-709 35 30 25 20 15 10 5 0 30.8% 24.7% Placebo (n-840) Drotrecogin alfa (activated) (n=850) Mortality (%) 6.1% absolute reduction in mortality
  • 53.
  • 54. Mortality and APACHE II Quartile Adapted from Figure 2, page S90, with permission from Bernard GR. Drotrecogin alfa (activated) (recombinant human activated protein C) for the treatment of severe sepsis. Crit Care Med 2003; 31[Suppl.]:S85-S90 APACHE II Quartile *Numbers above bars indicate total deaths Mortality (percent) 26:33 57:49 58:48 118:80
  • 55. Mortality and Numbers of Organs Failing Adapted from Figure 4, page S91, with permission from Bernard GR. Drotrecogin alfa (activated) (recombinant human activated protein C) for the treatment of severe sepsis. Crit Care Med 2003; 31[Suppl.]:S85-S90 Percent Mortality 0 10 20 30 40 50 60 1 2 3 4 5 Placebo Drotrecogin Number of Organs Failing at Entry
  • 56.
  • 57. Transfusion Strategy in the Critically Ill Figure 2A, page 414, reproduced with permission from Hebert PC, Wells G, Blajchman MA, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. N Engl J Med 1999; 340:409-417
  • 58.
  • 59.
  • 60.
  • 61.
  • 62.
  • 63.  
  • 64. Mechanical Ventilation of Sepsis-Induced ALI/ARDS
  • 65. % Mortality ARDSnet Mechanical Ventilation Protocol Results: Mortality Adapted from Figure 1, page 1306, with permission from The Acute Respiratory Distress Syndrome Network. N Engl J Med 2000;342:1301-1378
  • 66. Peak Airway Pressure Inspiratory Plateau Pressure PEEP (5 cm H 2 O 5 0
  • 67.
  • 68.
  • 69.
  • 70.
  • 71.
  • 72.
  • 73.
  • 74.
  • 75.
  • 76.
  • 77.
  • 78.
  • 79.
  • 80.
  • 81. Changing pH Has Limited Value Treatment Before After NaHCO3 (2 mEq/kg) pH 7.22 7.36 PAOP 15 17 Cardiac output 6.7 7.5 0.9% NaCl pH 7.24 7.23 PAOP 14 17 Cardiac output 6.6 7.3 Cooper DJ, et al. Ann Intern Med 1990; 112:492-498
  • 82.
  • 83.
  • 84.
  • 85.
  • 86. Phase 1 Barcelona declaration Phase 2 Evidence based guidelines Paediatric issues Phase 3 Implementation and education Surviving Sepsis
  • 87.
  • 88.
  • 89.
  • 90.
  • 91. Phase 1 Barcelona declaration Phase 2 Evidence based guideline Phase 3 Implementation and education Surviving Sepsis
  • 92.
  • 93.
  • 94.
  • 95.
  • 96.
  • 97. A clinician, armed with the sepsis bundles, attacks the three heads of severe sepsis: hypotension, hypoperfusion and organ dysfunction. Crit Care Med 2004; 320(Suppl):S595-S597
  • 98. Actual title of painting is “Hercules Kills Cerberus,” by Renato Pettinato, 2001. Painting hangs in Zuccaro Place in Agira, Sicily, Italy. Used with permission of artist and the Rubolotto family.
  • 100. Acknowledgment The SSC is grateful to R. Phillip Dellinger, MD, for his input into creation of this slide kit.

Notas do Editor

  1. This slide set and associated background notes are provided by the Surviving Sepsis Campaign (SSC) as a service to all those interested in furthering the cause of the campaign. Educators, using the slide set for lecture purposes, should select the slides that satisfy content needs and the time constraints of their lecture. Table of Content Slides 1 – 9: Introduction and Background Slides 10 – 85: Recommendations and Rationale Slides 86 – 90: Pediatric Considerations Slides 91 – 98: Phase III, Development of the Sepsis Bundles
  2. The Surviving Sepsis Campaign was initiated in 2002 by the European Society of Intensive Care Medicine, the International Sepsis Forum, and the Society of Critical Care Medicine with the intent to reduce mortality rates in severe sepsis by 25% in 5 years. An open invitation exists for unrestricted education grants from industry to help support this campaign. Thus far, education grants have come from Baxter Bioscience, Edwards Lifesciences, and Eli Lilly and Company.
  3. The campaign was divided into three phases to include the Barcelona declaration, creation of evidence-based guidelines, and implementation in education. Phase 1 began with the issuance of the Barcelona declaration at the European Society of Intensive Care Medicine meeting in Barcelona, Spain in 2002. The declaration proclaimed an attempt by the Surviving Sepsis Campaign to reduce mortality in severe sepsis by 25% in 5 years.
  4. Phase 2 of the campaign was targeted toward the creation of evidence-based guidelines in the management of severe sepsis.
  5. An unprecedented 11 international organizations, with interest and expertise in the management of the septic patient, came together as co-sponsors of the evidence-based guidelines.
  6. Forty-seven committee members from the 11 organizations worked over a year to finalize the guidelines. Of note, the decision was made to exclude from committee selection primary investigators who had recently participated in positive trials with implications for septic patients. Although this excluded leaders in the field, it minimized perception of influence on the guidelines.
  7. The guidelines were published in both Critical Care Medicine and in Intensive care Medicine , and are available on-line.
  8. The grading system built upon an adaptation from Sackett et al., which had previously been used by the Society of Critical Care Medicine in the Pulmonary Artery Consensus Conference published in Critical Care Medicine . The rationale for using this particular grading system was that the current guidelines built upon a document published as a supplement in Intensive Care Medicine in 2001 by the International Sepsis Forum which had used this grading system.
  9. The recommendations are listed in a logical order of encounter with the septic patient and the order does not imply listing by importance. Likewise, the grading system allows higher grades where clinical trials have been performed and do not necessarily reflect the committee’s implication of importance, as some of the more important recommendations received a grade E (expert opinion) since no clinical trials have been performed to validate these recommendations.
  10. The initial resuscitation of the patient is of utmost importance and frequently occurs in the emergency department or on hospital wards.
  11. The physiological changes occurring in patients with severe sepsis and septic shock are myriad and include changes that are clearly detrimental such as decreased contractility of the left and right ventricle, increased venous capacitance, increased pulmonary vascular resistance, and capillary leak. Increased ventricular compliance and sinus tachycardia are likely adaptive responses allowing the ventricle to maintain, and even manifest increased cardiac input, following volume resuscitation in despite decreased contractility. The decreased arteriolar resistance may also be adaptive, although when profound, produces detrimental and potentially lethal hypotension.
  12. The recommendations for initial resuscitation are centered around the Rivers trial (above) of early goal-directed therapy, which showed significant improvement in (a) hospital mortality, (b) 28-day mortality, and (c) 60-day mortality.
  13. The recommendation for initial resuscitation in patients with sepsis induced hypoperfusion, defined as hypotension (requiring vasopressors or lactic acidosis) is targeted toward the Rivers’ protocol.
  14. Previous literature supports equivalent tissue perfusion (measured by five different tissue perfusion parameters) between 65 mm Hg and 85 mm Hg of mean arterial blood pressure with norepinephrine in septic shock.
  15. The recommendations for initial resuscitation include those goals targeted in both the standard and early goal-directed therapy (EGDT) groups of the Rivers’ study to include CVP  8–12 mm Hg, mean arterial pressure  65 mm Hg, and a goal of urine output  .5 ml/kg/hr, as well as a central venous (superior vena cava) O 2 saturation of  70%, the additional target in the EGDT group. In addition, intubation and mechanical ventilation was performed if necessary to maintain an arterial saturation of 93% or greater.
  16. Again, based on the Rivers study, if volume resuscitation fails to achieve a mixed venous O2 sat of 70% or greater, packed red blood cells to a hematocrit of 30% and/or dobutamine to a max of 20  g/kg/min to achieve this goal is recommended.
  17. Appropriate cultures should be obtained from all potential sites of infection. In addition, a minimum of two blood cultures, of which at least one should be percutaneous and one from each vascular access site in place for  48 hours should be obtained.
  18. Although high-level evidence is not currently available, the early administration of intravenous antibiotics is a high priority in patients with severe sepsis, and should begin within the first hour of recognition of severe sepsis.
  19. Covering broad initially in patients with severe sepsis to include one or more drugs active against all likely bacterial or fungal pathogens is recommended. It is important to consider microorganisms susceptibility patterns in the community and hospital, which may vary from region to region.
  20. Equally important as broad initial coverage is the willingness of the physician to reassess antimicrobial regimen at 48–72 hours in an attempt to use microbiologic and clinical data to narrow the antibiotic coverage. In addition, if noninfectious causes are now thought to have likely been the reason for the patient’s deterioration and cultures are negative, antibiotics should be discontinued. This is important to prevent emergence of resistant organisms, which has become a major problem, as well as to reduce toxicity and cost.
  21. Early emphasis on identification of source control problems is a high priority to avoid morbidity and mortality. All patients should be evaluated for a focus of infection, amenable to source control measures, to include abscess drainage or tissue debridement. Following stabilization the clinician should move rapidly to achieve this goal. The potential physiologic upset of the measure chosen for source control should be considered (for example percutaneous drainage may be preferred over operative theatre intervention). All intravascular access devices that may be a source of infection should be removed and, in the absence of identified site, should be assumed to be a potential site.
  22. This picture demonstrates a 38-year-old man with pharyngitis who presents with high fever, leukocytosis, hypotension, elevated BUN/creatinine, and early evidence of coagulopathy who now has redness and swelling of the anterior neck and chest pain.
  23. An EKG obtained in this patient demonstrates a diffuse ST segment elevation (or PR depression) diagnostic of pericarditis, and in this case indicating the presence of mediastinitis requiring urgent operative drainage of the mediastinum in order to prevent mortality.
  24. Colloid or crystolloid resuscitation is considered equal. Colloids are associated with less peripheral edema and crystolloids with considerable less cost.
  25. Meta analyses reveal no difference between crystalloids and colloids in general populations of critically ill patients.
  26. The initial fluid resuscitation and ongoing resuscitation of patients with severe sepsis and tissue hypoperfusion is built around fluid challenges delivered over 30 minutes using either 500 – 1000 ml of crystolloid or 300 – 500 ml of colloids. These should be repeated based on response until tissue hypoperfusion is relieved or there is evidence of intolerance of fluid resuscitation, i.e. volume overload.
  27. Norepinephrine or dopamine, as combined inotrope/vasopressors (to match the sepsis-induced decrease in contractility and systemic vascular resistance) are considered equal choices as the initial vasopressor of choice. It is important to remember that vasopressors should be utilized not only when fluid resuscitation fails to reverse hypotension, but also during fluid resuscitation to maintain minimally adequate blood pressure while fluid resuscitation is administered in attempts to decrease vasopressor requirement.
  28. Considerable data (such as that shown above) indicates that epinephrine, although a combined inotrope/vasopressor, is not the best initial vasopressor of choice because of concerns with decrease in splanchnic blood flow. The study above comparing dopamine, norepinephrine, and epinephrine in moderate shock, and norepinephrine and epinephrine in severe shock supports epinephrine induced decrease in splanchnic blood flow.
  29. Although low-dose dopamine was routinely used for years in hopes of renal protection in patients with acute tissue hypoperfusion and multi-organ system dysfunction, and in combination with vasopressor level blood pressure support, it is now clear that low-dose dopamine does not improve outcome in these patient groups.
  30. Patients requiring vasopressors should have an arterial catheter in place so that sudden changes in blood pressure can be monitored and vasopressors can be titrated more easily. This may not be practical, however, during initial resuscitation in the emergency department or on hospital wards.
  31. Vasopressin levels are elevated during the initial presentation of septic shock and then decrease to basal levels over the next 48 to 96 hours. Since vasopressin levels are expected to be a normal body response to hypotension, this occurrence has been labeled as relative vasopressin deficiency and has led to the use of vasopressin in patients with septic shock.
  32. When patients with septic and cardiogenic shock are maintained at the same mean arterial blood pressure with vasopressors, it is noted that cardiogenic shock patients maintain elevated vasopressin levels while patients with septic shock over time have lower levels that approach baseline. In addition, prospective, randomized, blinded studies have demonstrated the potential for low-dose vasopressin to decrease or eliminate requirements of traditional pressors. However, as a pure vasopressor/vasopressin would be expected to decrease stroke volume and cardiac output as traditional vasopressors are replaced. This may be problematic, particularly in patients with significant decrease in ejection fraction and low baseline cardiac outputs.
  33. Although vasopressin has been demonstrated in some studies to improve renal function, there are other studies that raise concern about preservation of splanchnic perfusion. Vasopressin should not be considered a replacement for norepinephrine or dopamine as a first-line agent in septic shock. However, it may be considered in refractory shock despite high-dose conventional vasopressors or when high vasopressor requirements continue for 48 hours or longer. If used, it should be administered at very low doses, not to exceed .04 units/min in adults. Higher doses may be associated with coronary or mesenteric ischemia.
  34. This slide demonstrates radionuclide angiography in a patient during septic shock and following recovery. The top left panel shows end-diastole and demonstrates increased diastolic size of the ventricles (increased compliance), which is thought to be an adaptive mechanism. The top right image shows end-systole in this patient demonstrating a very low ejection fraction (little change in chamber size compared to end-diastole). The bottom two frames following recovery demonstrate a decrease in end-diastole volume, smaller ventricle at end systole and therefore significant improvement in ejection fraction.
  35. A significant contractility decrease may occur in some patients with septic shock. When cardiac output is being measured (either invasively or noninvasively) and a low cardiac output is present despite adequate fluid resuscitation, the consideration of adding dobutamine to raise cardiac output to a normal range is appropriate. It is important when this is done to continue to titrate vasopressors to maintain a mean arterial pressure of  65 mm Hg.
  36. Since patients with septic shock typically have a lactic acidosis, and since lactic acidosis is associated with a “oxygen debt”, the the possibility of improving outcome by reversing oxygen debt by producing supranormal oxygen delivery has led to multiple clinical trials in this area. Unfortunately, none of these trials have shown clinical outcome benefit, and one study (Hayes) suggested harm when very high level inotropes were used to drive oxygen delivery to supranormal levels. Therapy should therefore be targeted toward reversing clinical signs of tissue hypoperfusion and not toward an arbitrarily pre-defined level of oxygen delivery.
  37. The largest randomized prospective trial done to study the effect of stress-dose steroids in septic shock is the “French multi-center trial”, which targeted, “apriori,” patients who did not respond to ATCH stimulation as the group that would likely benefit from steroid therapy (slide shows results in that group). This group represented 77% of the population, and in this group significant improvement in survival by Kaplan-Meier curve with logistic regression adjustment for other variables influencing survival was shown.
  38. Single center studies also support significant clinical benefit as to morbidities and/or mortality.
  39. The Annane, Bollaert and Briegel studies used a variety of doses, routes of administration, and stop and tapering rules, but all three studies supported the ability of low-dose (stress-dose), i.e., 200-300 mg of hydrocortisone a day to improve clinical outcome. Although the Annane study has the highest evidence based support since it was a multicenter study with significant p-value on a priori survival cure logistic regression adjusted analysis, this study had a very rigorous entry requirement, requiring that patients be hypotensive despite therapy for at least an hour to be included. The Bollaert and Briegel studies, although smaller, suggest benefit of steroids in septic patients with vasopressor requirement only, a more commonly encountered group in clinical practice.
  40. The utilization of stress dose (“low-dose”) steroids is recommended for the treatment of patients with severe sepsis who continue to require significant amounts of vasopressors despite adequate fluid replacement. It should be noted that this recommendation includes a range of daily steroid dosing as well as alternative dosing methods to include intermittent dosing or continuous infusion. The rationale behind the construction of this recommendation is that it is a hybrid of regimens from the Ananne study, the Bollard study and the Briegel study.
  41. The apriori analysis group in the 2002 Annane study were patients who were non-responders to ACTH stimulation, i.e., relative adrenal insufficiency (see previous slide). This patient population was defined based on a previous Annane study showing that septic shock patients who were unable to raise their cortisol by 10 or more at either 30 or 60 minutes following 250  g ACTH stimulation, were at high risk for death. There was no evidence of benefit in non-responders (as shown above).
  42. Experts disagree on the best way to characterize relative adrenal insufficiency. In addition to the criteria used by Annane (incremental increase after high-dose ACTH (250  g) stimulation), other investigators have used random cortisol level, peak cortisol after stimulation, lower dose ACTH stimulation test, and combinations of these criteria.
  43. The use of ACTH stim test to define non-responders (post-stimulation cortisol  9  g/dl) as those who will have steroids continued is optional. If this approach is taken, steroid therapy is discontinued in responders.
  44. If the ACTH stimulation test is to be performed dexamethasone can be initiated pending performance of the ACTH stim test, as unlike hydrocortisone or methylprednisolone, it does not have cortisol-like metabolites, which interfere with the cortisol assay.
  45. Another option during steroid therapy is to taper and then discontinue steroids earlier when shock rapidly resolves (as opposed to a set course of 7 days).
  46. Corticosteroid dose may also be tapered at the end of 7-day therapy to avoid possible rebound effect of inflammation and decrease a blood pressure (see next slide).
  47. In this study by Keh and colleagues patients were randomized to low-dose steroids or placebo and then crossed over after three days. The patients going from steroids to placebo exhibited a significant pro-inflammatory rebound associated with increased vasopressor requirements.
  48. A final option for steroid therapy of septic shock includes the addition of fludrocortisone (a pure mineralocorticoid) . Fludrocortisone was utilized in the Annane study, but not in the Bollaert or Briegel studies. Hydrocortisone does have significant mineralocorticoid activity, although fludrocortisone is a pure mineralocorticoid. (See next slide.)
  49. 7 In a study by Witek-Janusek and colleagues, utilizing a rodent preparation of septic shock, a comparison was made among effect of intact adrenal gland, ablation of adrenal cortex function (ADRNX) and ablation of adrenal medullary function (MEDX) on survival. The ablation of the glucocorticoid producing cortex produced a significant increase in mortality, whereas ablation of the medulla (mineralocorticoids production) had no significant effect on survival, and was similar to the intact adrenal (see above). This type of animal evidence supports the importance of glucocorticoids and not mineralocorticoids in ameliorating sequelae of septic shock.
  50. Based on several studies demonstrating lack of efficacy when high-dose corticosteroids (up to a gram of methylprednisolone) are given during the first 24 hours of severe sepsis and septic shock, the use of corticosteroids greater than 300 mg a day is not recommended.
  51. A key modulator of the thrombin triggered coagulation response to sepsis is the activation of protein C. Inactive protein C zymogen is activated by a combination of the endothelial surface receptors (thrombin/thrombomodulin receptor, and the protein C receptor). In patients with severe sepsis, these endothelial receptors are stripped off the surface of the endothelium and can be identified in the circulation leading to decreased capability for activating protein C.[1] Once protein C is activated protein S is a co-factor for amplification of activity. 1. Faust SN, Levin M, Harrison OB, et al. Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N Engl J Med 2001; 345:408-416
  52. Activated protein C when administered in a blinded, randomized fashion to over 1600 patients with severe sepsis and septic shock produced a 6.1% absolute reduction in mortality.
  53. In considering patient selection for rhAPC, the patient should be full support, have an infection induced organ system dysfunction that is associated with a high risk of death, and have no absolute contraindications to drug use (significant risk of fatal hemorrhage such as previous hemorrhagic stroke or recent visceral trauma).
  54. The FDA labeling for rhAPC indicates use for patients with sepsis induced organ dysfunction associated with a high risk of death, such as APACHE II of 25 or greater. This is based on subset analysis of the four APACHE II quartiles in the rhAPC clinical trial showing that most of the benefit occurred in patients with APACHE II of 25 or greater.
  55. The European regulatory authority lists multiple organ failure as the indication for rhAPC therapy in severe sepsis. This is based on subset analysis indicating that patients with multiple organ failure are most likely to benefit.
  56. The SSC recommendation lists four patient findings that would be linked to high risk of death for which rhAPC is recommended. In addition to no absolute contraindications, relative contraindications should also be weighed.
  57. In 1999, Herbert al. published a large study that randomized a general population of ICU patients to receive either restrictive transfusion strategy in which transfusion occurred (1) when the hemoglobin decreased to less than 7g/dl to maintain a 7–9 g/dl versus (2) transfusing when the hemoglobin decreased to less than 10 g/dl to maintain 10–12 g/dl. There was no statistically significant difference in mortality in the two ICU patient groups, with a trend in survival favoring the restrictive transfusion strategy.
  58. Once tissue hypoperfusion has resolved, and in absence of the extenuating circumstances as listed, the transfusion threshold should be as it was in the restrictive group in the Herbert study.
  59. Although erythropoietin may be used for other accepted reasons such as chronic renal failure, it should not be used to treat sepsis related anemia in the absence of these other indications.
  60. Fresh frozen plasma should be reserved for the bleeding patient or for planned invasive procedures. In those circumstances targeting an INR of 1.5 or less would be appropriate.
  61. Antithrombin therapy is not recommended. One clinical trial performed in patients with severe sepsis demonstrated no benefit.
  62. An absolute threshold is recommended for transfusion of platelets in all patients with severe sepsis, a second range when there is significant bleeding risk, and a third threshold in the presence of bleeding or when invasive procedures are planned.
  63. This chest radiograph shows a patient with ARDS characterized by diffuse bilateral infiltrates.
  64. Sepsis is the most frequent cause of acute lung injury and acute respiratory distress syndrome (ARDS). Acute lung injury is the most common system dysfunction in sepsis and is associated with significant morbidity and mortality. Patients with severe lung injury, i.e., sepsis induced ARDS almost always require mechanical ventilation, and many patients with acute lung injury are also mechanically ventilated.
  65. The ARDSnet trial compared 6 ml/kg ideal body weight vs. 12 ml/kg ideal body weight (low tidal volume/high tidal volume comparison). The low tidal volume group demonstrated a significant decrease in mortality.
  66. Measurement of inspiratory plateau pressure allows estimation of the end inspiratory alveolar pressure as a marker of lung inflation. A .5 second end inspiratory typically allows this measurement.
  67. The recommendation for mechanical ventilation of sepsis induced ALI/ARDS is to reduce tidal volume (TV) over 1 to 2 hours to 6ml/kg predicted body weight (PBW—formula available on the ARDSnet and SSC websites) starting at 8ml/kg. In addition, inspiratory plateau pressure should be measured and maintained < 30 cm H2O. This may require further reduction of TV to as low as 4.0 ml/kg/PBW.
  68. In addition to avoiding lung overinflation during mechanical ventilation of ARDS by limiting tidal volume, it is also important to institute a minimum amount of PEEP that will prevent end-expiratory lung collapse. Because of the increased lung water and associated decreased compliance, end-expiratory lung collapse occurs at low levels of PEEP. Repeated closing and opening of lung with tidal excursion is thought to produce sheer force injury. There are two potential ways of setting minimal PEEP. One is to utilize the ARDSnet table (web site address) another more sophisticated method, not usually practical in the typical hospital environment, is measuring thoracopulmonary compliance and setting PEEP in an area of optimal compliance.
  69. Despite significant improvement in oxygen in 70% of patients proned in one large study there was no difference in clinical outcome through a 180 days. However, in patients with the severest of hypoxemia there was a suggestion of benefit.
  70. Pending additional clinical trials prone positioning remains unproven as a modality that will alter outcome in ARDS. However, based on the significant improvement in physiology with proning as well as improvement in oxygenation, the committee recommends that it be considered in ARDS patients who have potentially injurious levels of F1O2 or plateau pressure despite optimization of traditional mechanical ventilation. Patients at high risk from proning such as (a) hemodynamic instability, (b) placement of multiple anterior invasive devices/tubes/lines, or (c) morbid obesity are likely not good candidates for prone positioning. In that circumstance and in the presence of life-threatening hypoxemia, inhaled nitric oxide therapy could be considered as salvage therapy.
  71. In order to decrease the incidence of ventilator acquired pneumonia, the semirecumbent position should be utilized, unless contraindicated, in all mechanically ventilated septic patients. Although 30°–45° is often mentioned as the target elevation, 45° has the best supportive evidence.
  72. In mechanically ventilated septic patients, a weaning protocol should be in place to evaluate on a daily basis the likelihood of weaning and extubation. Protocol criteria should exist for preforming a spontaneous breathing trial at least daily.
  73. Options for spontaneous trial include low-level pressure support with CPAP of 5 or T-piece (humidified gas delivered to endotracheal tube off mechanical ventilator support).
  74. Certain criteria should be assessed and met prior to spontaneous breathing trial performance. If a spontaneous breathing trial is successful (typically frequency/tidal volume ratio < 105) after 30-60 minutes, serious consideration should be given for extubation.
  75. Most patients mechanically ventilated with severe sepsis require some degree of sedation and analgesia. However, overuse of these drugs leads to prolonged need for mechanical ventilation. It is therefore important to titrate sedation and analgesia to the minimal effective dose. This is likely best done using bolus administration so that the drug is only given when bedside evaluation indicates a lack of sedation or analgesia. When continuous infusion is needed there should be daily awakening and retitration to minimally effective doses to avoid oversedation and tissue accumulation of sedating agents.
  76. Neuromuscular blockade (NMB) is being used less and less in mechanically ventilated patients with severe sepsis. NMB beyond the initial stabilization period is associated with a significant incidence of prolonged neuromuscular blockade following discontinuation of NMB. Neuromuscular blockade should be avoided if possible. When utilized longer then 2–3 hours, NMB administration should be either (a) PRN bolus with drug administration only when a clearly identified patient need arises or (b) by continuous infusion with a twitch monitor. The twitch monitor is kept at a minimum of 2 or more twitches following a train of four delivery of electric signals. Neuromuscular blockade is primarily used to control patient respiratory rate (equal to or less than set ventilator rate). When patient rate control can be achieved with four out of four twitches that is optimal.
  77. Results of the van den Berghe trial demonstrated an impressive improvement in survival with intensive glycemic control.  Patients admitted to SICU mechanically ventilated  All patients received 200–300 g glucose/day on admission and continuous infusion intravenous insulin as needed to achieve target glucose level. – Conventional: titrate glucose to 180–200 mg/dL – Intensive: titrate glucose to 80–110 mg/dL  TPN or parenteral fluid within 24 hours of admission with 60% to 80% glucose calories
  78. The SSC recommendation uses a less stringent glucose threshold then that used by van den Berghe et al., recommending glucose be maintained < 150 mg/dl. Many hospitals may have difficulty securing the intense bedside resources needed to maintain levels between 80 and 110. Finney et al. also demonstrated improved outcome in critically ill patients when glucose was maintained at 110-145 mg/dl ( JAMA 2003; 290:2041-2047) It is important that patients who are receiving continuous infusion insulin also be receiving glucose in some form, either TPN, enteral or peripheral glucose infusion. Enteral nutrition is the preferred method of glucose delivery. The initial monitoring will need to be more intense requiring 30–60 minute monitoring. After glucose stabilization is achieved monitoring may be extended to 4 hours.
  79. In the absence of hemodynamic instability intermittent hemodialysis and continuous venovenous hemofiltration (CVVH) offer equal clinical outcome effects. Because intermittent hemodialysis is difficult to maintain in the presence of hemodynamic instability, CVVH is preferred in that circumstance.
  80. Literature supports that in patients with type 1 lactic acidosis (cellular hypoxia) and pH of  7.15, there is no hemodynamic benefit associated with pH correction. Presence of lactate acidosis indicates cellular hypoxia and anaerobic metabolism. Correcting the pH does not alter the hypoxic cellular state.
  81. Cooper and colleagues compared equimolar amounts of sodium bicarbonate and normal saline in patients with vasopressor requiring lactic acidosis (pH range down to 7.15 with mean 7.23) and demonstrated that although pH was significantly increased with bicarbonate versus normal saline there was no difference in cardiac output. There was also no difference between the two groups as to weaning of vasopressors.
  82. Numerous clinical trials containing significant numbers of sepsis patients have demonstrated ability of DVT prophylaxis to decrease incidence of deep vein thrombosis and pulmonary embolism. Either unfractionated heparin or low molecular heparin is recommended. In patients with contraindication for heparin, mechanical compression devices of the lower extremities are recommended unless there is contraindications to compression device, i.e. severe peripheral vascular disease or leg injury. High risk patients should have combination pharmacologic and mechanical therapy considered.
  83. Patients with severe sepsis frequently have literature identified risk factors for stress ulcer bleeding including mechanical ventilation, coagulopathy and hypotension.
  84. Stress ulcer prophylaxis is recommended and H2 receptive blockers are the therapy of choice. Proton pump inhibitors have been demonstrated to show equivalence in raising stomach pH although no clinical studies have been performed.
  85. Many patients with severe sepsis and septic shock have terminal illnesses with short expected life spans. In these patients the highly unlikely benefit of therapy and the potential discomfort associated with aggressive therapy warrants serious consideration for limitation of support with implementation of comfort care, emotional support to the patient and family, and pain control.
  86. Although there is limited data available from prospective clinical trials in pediatric septic patients, there are considerable differences in the pathophysiology of pediatric sepsis that warrants comment.
  87. Fluid resuscitation of pediatric patients is weight based and aggressive, with initial resuscitation of 20ml/kg and often up to 40–60ml/kg required during the initial resuscitation. Blood pressure itself is not a reliable endpoint for resuscitation. Physical exam, urine output, and pulse response are the primary response monitors.
  88. The hemodynamic profile of pediatric sepsis is quite variable. Dopamine with its combined inotrope and vasopressor characteristics is recommended for pediatric hypotension because of the tendency for a lower cardiac output in this patient population. Epinephrine or norepinephrine are then added for dopamine refractory shock. When cardiac output is measured, dobutamine is recommended for low cardiac output states. Inhaled nitric oxide may be useful in neonates who are septic with post-partum pulmonary hypertension.
  89. Physical exam findings indicating successful resuscitation include a capillary refill < 2sec, warm extremities, and normal mental status. Other objective targets include urine output > 1ml/kg/hr and normalization of lactate, and as in the adult, central venous O 2 sat  70%.
  90. As in adults, steroids are recommended for children with catecholamine resistance and suspected or proven adrenal insufficiency. Activated protein C has not been studied in pediatric severe sepsis. Unlike adults GM-CSF has been shown to be of benefit in neonates in circumstances of neutropenia and sepsis. ECMO, not recommended in adults, may be useful in children with refractory shock or respiratory failure.
  91. The third and most important phase of the Surviving Sepsis Campaign is implementation and education, since only behavior change will effect clinical outcome improvement. The creation of guidelines, although an important component of the process, does not in itself change behavior.
  92. The SSC sepsis change bundle description and process is covered in depth on the SSC/IHI web site accessible through either of the two web sites above. There is a direct link available from home page of the SSC web site. From the home page of the IHI web site select Topics  Critical Care  Sepsis.